Heidelberg Pharma AG (DE:HPHA)
XETRA:HPHA
Want to see DE:HPHA full AI Analyst Report?
Top Page
Heidelberg Pharma AG
(XETRA:HPHA)
Select Model
Select Model
Rating:43Neutral
Price Target:
€2.50
▲(4.17% Upside)
Action:Reiterated
Date:05/09/26
The score is primarily weighed down by weak financial performance: large ongoing losses, persistent cash burn, and the move to negative equity, which heightens funding and solvency risk. Technicals add pressure as the stock trades below major moving averages with negative MACD. Valuation provides limited support because the company is loss-making and offers no dividend yield.
Positive Factors
Proprietary ATAC platform
Owning a proprietary ATAC antibody‑drug conjugate platform provides a durable scientific moat: it enables multiple internal programs, creates potential for out‑licensing or partnerships, and concentrates R&D know‑how that can produce multiyear value beyond single trials.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow is a durable risk: it forces reliance on external financing or partner funding, increases dilution risk, and constrains the firm’s ability to fund clinical programs independently over the medium term without material capital raises.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary ATAC platform
Owning a proprietary ATAC antibody‑drug conjugate platform provides a durable scientific moat: it enables multiple internal programs, creates potential for out‑licensing or partnerships, and concentrates R&D know‑how that can produce multiyear value beyond single trials.
Read all positive factors
Heidelberg Pharma AG (HPHA) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€127.25M
Dividend YieldN/A
Average Volume (3M)8.49K
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue Growth-53.03%
EPS Growth-94.45%
CountryDE
Employees105
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.86
Shares Outstanding46,784,317
10 Day Avg. Volume3,574
30 Day Avg. Volume8,494
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-12.31
Price to Sales (P/S)92.22
P/FCF Ratio-4.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)€12.90M
Heidelberg Pharma AG Business Overview & Revenue Model
Company Description
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in t...
How the Company Makes Money
null...
Heidelberg Pharma AG Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
14
Very Negative
| Breakdown | Feb 2026 | Feb 2025 | Feb 2024 | Feb 2023 | Feb 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.46M | 6.85M | 9.86M | 18.51M | 1.75M |
| Gross Profit | -1.63M | 4.20M | 6.61M | 13.83M | -2.96M |
| EBITDA | -44.63M | -18.37M | -18.71M | -16.19M | -24.83M |
| Net Income | -42.28M | -19.38M | -20.35M | -19.70M | -26.63M |
Balance Sheet | |||||
| Total Assets | 38.14M | 60.72M | 70.35M | 100.58M | 21.73M |
| Cash, Cash Equivalents and Short-Term Investments | 14.98M | 29.42M | 43.44M | 81.33M | 6.14M |
| Total Debt | 1.16M | 21.97M | 5.83M | 15.98M | 10.63M |
| Total Liabilities | 49.05M | 29.85M | 21.01M | 33.94M | 15.03M |
| Stockholders Equity | -10.92M | 30.87M | 49.34M | 66.64M | 6.70M |
Cash Flow | |||||
| Free Cash Flow | -31.73M | -30.04M | -34.63M | -9.48M | -28.00M |
| Operating Cash Flow | -31.60M | -29.59M | -33.67M | -8.86M | -26.61M |
| Investing Cash Flow | -135.05K | -449.13K | 5.85M | -597.57K | -1.40M |
| Financing Cash Flow | 18.35M | 16.08M | -10.05M | 84.00M | 29.17M |
Heidelberg Pharma AG Technical Analysis
Negative
2.40
Price Trends
2.86
Negative
2.90
Negative
3.09
Negative
Market Momentum
-0.03
Positive
43.50
Neutral
43.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:HPHA, the sentiment is Negative. The current price of 2.4 is below the 20-day moving average (MA) of 2.79, below the 50-day MA of 2.86, and below the 200-day MA of 3.09, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 43.50 is Neutral, neither overbought nor oversold. The STOCH value of 43.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:HPHA.
Heidelberg Pharma AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | €1.41B | -63.32 | 4.98% | ― | ― | ― | |
51 Neutral | €367.60M | -10.76 | -16.02% | ― | -36.17% | 48.61% | |
50 Neutral | €65.76M | -4.72 | -337.77% | ― | -9.17% | -5.52% | |
43 Neutral | €127.25M | -8.36 | -5460.56% | ― | -53.03% | -94.45% |
* Healthcare Sector Average
DE:HPHA
Heidelberg Pharma AG
2.75
-0.59
-17.66%
DE:BIO
Biotest
39.20
-3.80
-8.84%
DE:BNN
B.R.A.I.N. Biotechnology Research and Information Network
3.24
1.13
53.55%
DE:CNW
co.don AG
0.01
>-0.01
-7.14%
DE:MDG1
Medigene
0.03
-0.08
-72.73%
DE:FYB
Formycon AG
19.66
-2.49
-11.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.